IP Library Granted Patent US 9,023,641
Granted Patent B2
US 9,023,641 · App. 11/568,832 · Granted May 5, 2015

Microfluidic device and leucocyte antigen mediated microfluidic assay

Inventors: Rodolfo R. Rodriguez (Cary, NC); Douglas J. Darr (Timberlake, NC)
Assignee: Advanced Animal Diagnostics
G01N33/56972B01L3/50273G01N2015/008B01L3/5027B01L2300/0816B01L2300/0867B01L2400/0406G01N2333/8107
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,023,641
App. No.
11/568,832
Granted
May 5, 2015
Kind
B2
Abstract

The present invention relates to an leucocyte antigen mediated microfluidic assay and a microfluidic device for analyzing a subjects' body fluids containing leucocytes to determine if the subject has been previously exposed to a predetermined antigen.

Claims (47)

1. A leucocyte antigen mediated microfluidic assay method for testing a leucocyte-containing body fluid from a subject for prior exposure to a predetermined antigen which would have caused leucocytes to become presensitized to the antigen comprising:

performing a first test comprising the steps of:

a) placing a microvolume of a first sample of the subject's leucocyte-containing body fluid in a first sample microchamber;

b) transporting, by capillary action or by use of a micropump, the first sample body fluid to a first reaction microchamber containing the predetermined antigen and α 2 -macroglobulin and allowing reaction for a predetermined time;

c) transporting, by capillary action or by use of a micropump, the reacted first sample body fluid to a first observation microchamber;

d) mixing one or more leucocyte observation colorants with the reacted first sample body fluid, wherein mixing occurs either during transport to the observation microchamber or in the observation microchamber;

e) optically performing an optical scan of the reacted first sample body fluid in the first observation microchamber to find the leucocytes in the reacted first sample body fluid; and measuring one or more measurement factors of the leucocytes;

performing a second test comprising the steps of:

a) placing a microvolume of a second sample of the subject's leucocyte-containing body fluid in a second sample microchamber;

b) transporting, by capillary action or by use of a micropump, the second sample body fluid to an antigen-free second reaction microchamber containing α 2 -macroglobulin but not containing the antigen and allowing reaction for the predetermined time;

c) transporting, by capillary action or by use of a micropump, the second sample body fluid to a second observation microchamber;

d) mixing the same leucocyte observation colorants as the first test with the reacted second sample body fluid, wherein mixing occurs either during transport to the second observation microchamber or in the second observation microchamber;

e) optically performing an optical scan of the reacted second sample body fluid in the second observation microchamber to find the leucocytes in the reacted second sample body fluid; and measuring the same leucocyte measurement factor measured in the first test;

determining whether leucocytes have reacted with the antigen by comparing the results of the first optical scan to the second optical scan, wherein any differences between the two scans are indicative of reaction of leucocytes with the antigen due to the leucocytes having been presensitized to the antigen via prior exposure.

2. The assay method of claim 1 wherein the leucocytes are T lymphocytes or neutrophils.

3. The assay method of claim 2 , wherein the T lymphocytes are memory T lymphocytes.

4. The assay method of claim 1 wherein the optical scans are accomplished by multi-wavelength fluorescence image analysis.

5. The assay method of claim 1 wherein the entire method is performed on a single disposable device.

6. The assay method of claim 1 wherein the measurement factors that are measured are morphological factors, spectral factors or both.

7. The assay method of claim 1 wherein a plurality of predetermined antigens are placed in the first reaction microchamber.

8. The assay method of claim 1 wherein the reaction of leucocytes with the antigen is determined by either measuring the number, relative intensity or both of the subject's reactive leucocytes while comparing the results of the first optical scan to the second.

9. The assay method of claim 1 wherein the body fluid is whole blood.

10. The assay method of claim 9 , wherein: the leucocytes are T lymphocytes or neutrophils; the optical scans are accomplished by multi-wavelength fluorescence image analysis; the entire method is performed on a single disposable device;

the measurement factors that are measured are morphological factors, spectral factors or both; and

the reaction of leucocytes with the antigen is determined by either measuring the number, relative intensity or both of the subject's reactive leucocytes while comparing the results of the first optical scan to the second.

11. The assay method of claim 1 , wherein: the leucocytes are T lymphocytes or neutrophils; the optical scans are accomplished by multi-wavelength fluorescence image analysis; the entire method is performed on a single disposable device;

the measurement factors that are measured are morphological factors, spectral factors or both; and

the reaction of leucocytes with the antigen is determined by either measuring the number, relative intensity or both of the subject's reactive leucocytes while comparing the results of the first optical scan to the second.

12. A leucocyte antigen mediated microfluidic assay method for testing a leucocyte-containing body fluid from a subject for prior exposure to a predetermined antigen which would have caused leucocytes to become presensitized to the antigen comprising

performing a first test comprising the steps of:

a) placing a microvolume of a first sample of the subject's leucocyte-containing body fluid in a first sample microchamber;

b) transporting, by capillary action or by use of a micropump, the first sample body fluid to a first reaction microchamber containing the predetermined antigen and α 2 -macroglobulin and allowing reaction for a predetermined time;

c) mixing one or more leucocyte observation colorants with the reacted first sample body fluid;

d) optically performing an optical scan of the reacted first sample body fluid in the first reaction microchamber to find the leucocytes in the reacted first sample body fluid; and measuring one or more measurement factors of the leucocytes;

performing a second test comprising the steps of:

a) placing a microvolume of a second sample of the subject's leucocyte containing body fluid in a second sample microchamber;

b) transporting, by capillary action or by use of a micropump, the second sample body fluid to an antigen-free second reaction microchamber containing α 2 -macroglobulin but not containing the antigen and allowing reaction for the predetermined time;

c) mixing the same leucocyte observation colorants as the first test with the reacted second sample body fluid;

d) optically performing an optical scan of the reacted second sample body fluid in the second reaction microchamber to find the leucocytes in the reacted second sample body fluid; and measuring the same at least one leucocyte measurement factor measured in the first test; and

determining whether leucocytes have reacted with the antigen by comparing the results of the first optical scan to the second optical scan, wherein any differences between the two scans are indicative of reaction of leucocytes with the antigen due to the leucocytes having been presensitized to the antigen via prior exposure.

13. The assay method of claim 12 wherein the body fluid is whole blood.

14. The assay method of claim 13 , wherein: the leucocytes are T lymphocytes or neutrophils;

the optical scans are accomplished by multi-wavelength fluorescence image analysis; the entire method is performed on a single disposable device; the measurement factors that are measured are morphological factors, spectral factors or both; and

the reaction of leucocytes with the antigen is determined by either measuring the number, relative intensity or both of the subject's reactive leucocytes while comparing the results of the first optical scan to the second.

15. The assay method of claim 12 , wherein: the leucocytes are T lymphocytes or neutrophils; the optical scans are accomplished by multi-wavelength fluorescence image analysis; the entire method is performed on a single disposable device;

the measurement factors that are measured are morphological factors, spectral factors or both; and

the reaction of leucocytes with the antigen is determined by either measuring the number, relative intensity or both of the subject's reactive leucocytes while comparing the results of the first optical scan to the second.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Oct 23, 2018
From: SILICON VALLEY BANK
To: ADVANCED ANIMAL DIAGNOSTICS, INC.
Reel/Frame 047276/0944 →
SECURITY INTEREST Recorded May 2, 2017
From: ADVANCED ANIMAL DIAGNOSTICS, INC.
To: CULTIVIAN SANDBOX FOOD & AGRICULTURE FUND II, L.P.; INTERSOUTH PARTNERS VII, L.P.; SANDBOX ADVANTAGE FUND, L.P.; ORIGAMI CAPITAL PARTNERS, LLC; MIDDLELAND AG FUND II, L.P.
Reel/Frame 042204/0515 →
SECURITY INTEREST Recorded Apr 3, 2017
From: ADVANCED ANIMAL DIAGNOSTICS, INC.
To: CULTIVIAN SANDBOX FOOD & AGRICULTURE FUND II, L.P.; INTERSOUTH PARTNERS VII, L.P.; SANDBOX ADVANTAGE FUND, L.P.; ORIGAMI CAPITAL PARTNERS, LLC; HANNAN, JTWROS, KAREN LEE AND ROBERT E.; GREENBAUM, GARY R.
Reel/Frame 041834/0684 →
SECURITY INTEREST Recorded Oct 20, 2016
From: ADVANCED ANIMAL DIAGNOSTICS, INC.
To: INTERSOUTH PARTNERS VII, L.P.; CULTIVAN SANDBOX FOOD & AGRICULTURE FUND II, L.P.; SANDBOX ADVANTAGE FUND, L.P.; LABORATORY CORPORATION OF AMERICA HOLDINGS
Reel/Frame 040079/0926 →
SECURITY INTEREST Recorded Oct 20, 2016
From: ADVANCED ANIMAL DIAGNOSTICS, INC.
To: SILICON VALLEY BANK
Reel/Frame 040074/0453 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2009
From: RODRIGUEZ, RODOLFO R.
To: ADVANCED ANIMAL DIAGNOSTICS
Reel/Frame 023262/0310 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2009
From: DARR, DOUGLAS J.
To: ADVANCED ANIMAL DIAGNOSTICS
Reel/Frame 023182/0783 →
Continuity (2)
Provisional Application 60570543 · May 13, 2004
Related Publication 20090011451A1 · Jan 8, 2009